WOUND MANAGEMENT TECHNOLOGIES, INC. (OTCMKTS:WNDM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

WOUND MANAGEMENT TECHNOLOGIES, INC. (OTCMKTS:WNDM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

Effective January 31, 2019, John Siedhoff resigned as Chairman and member of the Board of Directors of Wound Management Technologies, Inc. (the “Company”). Mr. Siedhoff did not resign as a result of a disagreement with the Company.

Mr. Jim Stuckert, a Company Board member since 2015 and retired Chairman and Chief Executive Officer of J.J.B. Hilliard, W.L. Lyons, LLC, assumed the role of Chairman effective February 1, 2019.

About WOUND MANAGEMENT TECHNOLOGIES, INC. (OTCMKTS:WNDM)

Wound Management Technologies, Inc., formerly MB Software, Inc., distributes collagen-based wound care products to healthcare providers, such as physicians, clinics and hospitals. The Company’s subsidiaries include Wound Care Innovations, LLC (WCI), Resorbable Orthopedic Products, LLC and Innovate OR, Inc. The Company’s WCI provides CellerateRX product in the wound care market. CellerateRX is a medical device for use on all acute and chronic wounds, except third degree burns. CellerateRX is offered in both gel and powder form. WCI expanded its CellerateRX product line to include CellerateRX Surgical products.

An ad to help with our costs